全文获取类型
收费全文 | 2873篇 |
免费 | 166篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 158篇 |
妇产科学 | 222篇 |
基础医学 | 318篇 |
口腔科学 | 44篇 |
临床医学 | 192篇 |
内科学 | 524篇 |
皮肤病学 | 45篇 |
神经病学 | 101篇 |
特种医学 | 201篇 |
外科学 | 391篇 |
综合类 | 177篇 |
一般理论 | 1篇 |
预防医学 | 133篇 |
眼科学 | 75篇 |
药学 | 144篇 |
中国医学 | 42篇 |
肿瘤学 | 279篇 |
出版年
2023年 | 12篇 |
2022年 | 32篇 |
2021年 | 46篇 |
2020年 | 42篇 |
2019年 | 53篇 |
2018年 | 57篇 |
2017年 | 52篇 |
2016年 | 67篇 |
2015年 | 87篇 |
2014年 | 94篇 |
2013年 | 111篇 |
2012年 | 148篇 |
2011年 | 145篇 |
2010年 | 130篇 |
2009年 | 115篇 |
2008年 | 103篇 |
2007年 | 105篇 |
2006年 | 113篇 |
2005年 | 102篇 |
2004年 | 84篇 |
2003年 | 70篇 |
2002年 | 61篇 |
2001年 | 66篇 |
2000年 | 68篇 |
1999年 | 89篇 |
1998年 | 75篇 |
1997年 | 89篇 |
1996年 | 76篇 |
1995年 | 48篇 |
1994年 | 50篇 |
1993年 | 64篇 |
1992年 | 37篇 |
1991年 | 44篇 |
1990年 | 44篇 |
1989年 | 63篇 |
1988年 | 39篇 |
1987年 | 35篇 |
1986年 | 35篇 |
1985年 | 34篇 |
1984年 | 18篇 |
1982年 | 20篇 |
1981年 | 21篇 |
1980年 | 16篇 |
1979年 | 24篇 |
1977年 | 15篇 |
1976年 | 13篇 |
1974年 | 13篇 |
1973年 | 12篇 |
1972年 | 16篇 |
1966年 | 11篇 |
排序方式: 共有3066条查询结果,搜索用时 15 毫秒
91.
Two alpha-globin structural mutants were mapped to their encoding loci by in vitro translation of hybrid-selected alpha 1- and alpha 2-globin mRNA. The more highly expressed mutant, alpha Spanish Town (alpha 27Val), is encoded at the alpha 2 locus and the less expressed mutant, alpha Fort de France (alpha 45Arg), is encoded at the alpha 1 locus. These results further define the distribution of alpha-globin structural mutations within the alpha-globin gene cluster and substantiate the dominant role of the alpha 2-globin locus in alpha- globin expression. 相似文献
92.
茶多酚治疗慢性酒精性肝损伤的实验研究 总被引:8,自引:0,他引:8
目的 建立酒精性肝病大鼠模型,观察茶多酚对酒精性肝病大鼠血清氨基转移酶活性和肝脏病理变化的影响,探讨茶多酚对酒精性肝损伤的防治作用。 方法 SD大鼠分成3组:酒精组(酒精7g·kg-1·d-1灌胃)、茶多酚组(酒精7g·kg-1·d-1 茶多酚0.25g·kg-1·d-1灌胃)和对照组(等渗盐水灌胃)。各组分别于4周末、12周末和24周末处死大鼠留取肝脏标本,用于HE染色和Masson染色。 结果 酒精组大鼠血清氧基转移酶水平较对照组升高,茶多酚组大鼠与酒精组相比,其值有明显降低,差异有统计学意义(P<0.05)。HE染色显示酒精组大鼠肝细胞浆出现不同程度的脂肪变性,小叶各带可见不同程度的点、灶状或片状坏死,24周大鼠可见桥接坏死。Masson三色染色可见24周大鼠汇管区边缘有绿染胶原纤维包绕增生,肝窦中可见绿染胶原纤维分布。茶多酚组肝脂肪变和炎症程度轻于酒精组,未发现桥接坏死。 结论 茶多酚对酒精性肝损伤具有一定的保护作用。 相似文献
93.
Mehmet SA?LAM Serhat K?SEO?LU Mükerrem HAT?PO?LU Hac? Hasan ESEN Ekrem K?KSAL 《Journal of applied oral science : revista FOB》2015,23(1):33-41
Objectives
Sumac (Rhus coriaria L.) is widely used spice which has several properties such as antioxidant, anti-inflammatory and antimicrobial. The purpose of this animal study was to evaluate the effects of sumac extract on levels of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin (OPG) expression, serum oxidative status, and alveolar bone loss in experimental periodontitis.Material and Methods
Twenty-four Wistar rats were separated into three groups: non-ligated (NL, n=8), ligature only (LO, n=8), and ligature and treated with sumac extract (S, n=8) (20 mg/kg per day for 11 days). A 4/0 silk suture was placed around the mandibular right first molars subgingivally; after 11 days, the rats were sacrificed, and alveolar bone loss was histometrically measured. The detection of RANKL and OPG were immunohistochemically performed. Levels of serum total antioxidant status (TAS)/total oxidant status (TOS), and oxidative stress index (OSI) were also analyzed.Results
Alveolar bone loss was significantly greater in the LO group compared to the S and NL groups (p<0.05). The number of inflammatory cell infiltrate (ICI) and osteoclasts in the LO group was significantly higher than that of the NL and S groups (p<0.05). The number of osteoblasts in the LO and S groups was significantly higher than that of the NL group (p<0.05). There were significantly more RANKL-positive cells in the LO group than in the S and NL groups (p<0.05). OPG-positive cells were higher in S group than in LO and NL groups (p<0.05). TOS and OSI levels were significantly reduced in S group compared to LO group (P<0.05) and TAS levels were similar in S and NL group (p>0.05).Conclusions
The present study showed that systemic administration of sumac extract may reduce alveolar bone loss by affecting RANKL/OPG balance, TOS and OSI levels in periodontal disease in rats. 相似文献94.
95.
甲状腺术后瘢痕组织是甲状腺局部分切除术后由于手术方式及缝线填充而形成的组织,甲状腺术后瘢痕组织形成及其发生发展过程同一般的组织损伤修复病理过程一样,为渐进老化阶段的结缔组织,其内小血管稀少,胶原纤维增多[1]。由于甲状腺术后瘢痕组织其质地较硬,活动性差,超声声像图上表现缺乏典型特征,与癌灶极其相似,因此鉴别较困难。本文将介绍超声对于甲状腺术后的随诊应用,分析甲状腺术后瘢痕组织的超声检查特点并着重介绍超声动态观察甲状腺术后瘢痕组织的应用及其发展前景。 相似文献
96.
97.
Ulrike Rottensteiner Bapi Sarker Dominik Heusinger Diana Dafinova Subha N. Rath Justus P. Beier Ulrich Kneser Raymund E. Horch Rainer Detsch Aldo R. Boccaccini Andreas Arkudas 《Materials》2014,7(3):1957-1974
In addition to good mechanical properties needed for three-dimensional tissue engineering, the combination of alginate dialdehyde, gelatin and nano-scaled bioactive glass (45S5) is supposed to combine excellent cellular adhesion, proliferation and differentiation properties, good biocompatibility and predictable degradation rates. The goal of this study was to evaluate thein vitro and in vivo biocompatibility as a first step on the way to its use as a scaffold in bone tissue engineering. In vitro evaluation showed good cell adherence and proliferation of bone marrow derived mesenchymal stem cells seeded on covalently crosslinked alginate dialdehyde-gelatin (ADA-GEL) hydrogel films with and without 0.1% nano-Bioglass®(nBG). Lactate dehydrogenase (LDH)- and mitochondrial activity significantly increased in both ADA-GEL and ADA-GEL-nBG groups compared to alginate. However, addition of 0.1% nBG seemed to have slight cytotoxic effect compared to ADA-GEL. In vivo implantation did not produce a significant inflammatory reaction, and ongoing degradation could be seen after four weeks. Ongoing vascularization was detected after four weeks. The good biocompatibility encourages future studies using ADA-GEL and nBG for bone tissue engineering application. 相似文献
98.
Fabian Stimpfle Athanasios Karathanos Michal Droppa Janina Metzger Dominik Rath Karin Müller Elli Tavlaki Elke Schäffeler Stefan Winter Matthias Schwab Meinrad Gawaz Tobias Geisler 《Thrombosis research》2014
Aims
Only limited data exist about the role of point of care CYP2C19 testing in the acute setting in the early phase of acute coronary syndromes (ACS). Therefore, the present study was designed to investigate the impact of CYP2C19 loss-of–function point-of-care (POC) genotyping in patients presenting with acute coronary syndromes (ACS) and treated with dual antiplatelet therapy in the emergency setting.Methods and Results
137 subjects with ACS scheduled for percutaneous coronary intervention were consecutively enrolled. Pre- and on-treatment platelet aggregation was assessed by multiple electrode aggregometry (MEA) after stimulation with adenosine diphosphate (ADP). Patients were loaded according to current guideline adherent indications and contraindications for use of P2Y12 inhibitors in ACS. POC genotyping for CYP2C19*2 was performed in the emergency room after obtaining a buccal swab using the Spartan RX CYP2C19 system and obtaining patient’s informed consent. Prasugrel and ticagrelor treated patients had significantly lower PR compared to clopidogrel-treated patients. The benefits of prasugrel and ticagrelor compared to clopidogrel treated patients in terms of platelet inhibition were more pronounced in CYP2C19*2 carriers. Non-carriers showed similar inhibition regardless of particular P2Y12 inhibitor treatment. Statistical analyses adjusting for factors associated with response (e.g. smoking) revealed that CYP2C19*2 allele carrier status and loading with different type of P2Y12 receptor blockers were significant predictors of on-treatment platelet reactivity in the early phase of ACS.Conclusion
The results of this pilot study of treatment of patients in the early phase of ACS indicate that CYP2C19*2 POC genotyping might help to identify patients at risk with poor response to clopidogrel treatment, thereby benefiting from reloading and switching to alternative P2Y12 receptor inhibition. 相似文献99.
100.
Ben Gold Maneesh Pingle Steven J. Brickner Nilesh Shah Julia Roberts Mark Rundell W. Clay Bracken Thulasi Warrier Selin Somersan Aditya Venugopal Crystal Darby Xiuju Jiang J. David Warren Joseph Fernandez Ouathek Ouerfelli Eric L. Nuermberger Amy Cunningham-Bussel Poonam Rath Tamutenda Chidawanyika Haiteng Deng Ronald Realubit J. Fraser Glickman Carl F. Nathan 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(40):16004-16011
Existing drugs are slow to eradicate Mycobacterium tuberculosis (Mtb) in patients and have failed to control tuberculosis globally. One reason may be that host conditions impair Mtb’s replication, reducing its sensitivity to most antiinfectives. We devised a high-throughput screen for compounds that kill Mtb when its replication has been halted by reactive nitrogen intermediates (RNIs), acid, hypoxia, and a fatty acid carbon source. At concentrations routinely achieved in human blood, oxyphenbutazone (OPB), an inexpensive anti-inflammatory drug, was selectively mycobactericidal to nonreplicating (NR) Mtb. Its cidal activity depended on mild acid and was augmented by RNIs and fatty acid. Acid and RNIs fostered OPB’s 4-hydroxylation. The resultant 4-butyl-4-hydroxy-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione (4-OH-OPB) killed both replicating and NR Mtb, including Mtb resistant to standard drugs. 4-OH-OPB depleted flavins and formed covalent adducts with N-acetyl-cysteine and mycothiol. 4-OH-OPB killed Mtb synergistically with oxidants and several antituberculosis drugs. Thus, conditions that block Mtb’s replication modify OPB and enhance its cidal action. Modified OPB kills both replicating and NR Mtb and sensitizes both to host-derived and medicinal antimycobacterial agents.Some bacterial infections can be cured with a single dose of an antibiotic, and most others can be cured with administration of one drug over several days or weeks. In contrast, routine treatment of drug-sensitive tuberculosis (TB) takes 2 mo of therapy with four drugs and an additional 4 mo with two drugs to reduce the 2-y relapse rate below 5%. The difficulty of completing prolonged treatment is a major reason for emergence of drug resistance. When the infecting strain is resistant to isoniazid and rifampin, the two drugs recommended for all 6 mo of treatment, cure often requires 2 y of daily administration of toxic, expensive, second-line agents that are often unavailable at the point of care. When the causative strain is additionally resistant to a quinolone and an aminoglycoside, the resultant “extensively drug-resistant” TB was fatal to 80% of patients in a leading center (1), although complex multidrug regimens have achieved higher cure rates in populations not previously exposed to the additional drugs (2). In addition to sharing air with someone with TB, leading risk factors for contracting the disease are malnutrition, HIV infection, diabetes, and exposure to smoke from cigarettes or cooking fires (3). These epidemiological challenges exacerbate problems of inadequate diagnostic technology and limited access to drug susceptibility testing and to drugs. Control of the pandemic is not in sight (3).It is widely hypothesized that treatment of TB is protracted because nonreplicating (NR) subpopulations of bacilli are phenotypically tolerant to drugs that were selected for activity against replicating (R) Mycobacterium tuberculosis (Mtb) (4). Mtb can occupy diverse microenvironments in the host. Evidence from auxotrophs, analyses of gene expression, and direct and indirect biochemical measurements in vivo or ex vivo in experimental animals and people suggest that such environments expose Mtb to acid, hypoxia, reactive nitrogen intermediates (RNIs), oxidative stress, carbohydrate deficiency, and metal starvation or intoxication, and require Mtb to metabolize fatty acids or cholesterol (5–17). In vitro, many of the same conditions can make Mtb relatively refractory to killing by the standard agents, except for pyrazinamide, which is only effective at a low pH.Thus, there is a need for a high-throughput screen (HTS) for compounds that kill Mtb when the Mtb has been rendered NR by a combination of physiologically relevant host-imposed conditions. We were encouraged to devise such a screen by recent discoveries of a class of compounds that kill Mtb only when it is NR (18), an antibiotic in clinical use for other infections that kills NR Mtb better than R Mtb (19), and a compound that kills NR and R Mtb equally well (20). Unfortunately, only one of those compounds is an approved drug, and even if it were of proven utility in TB, its price would preclude its use by most of those who need it. We decided to screen other existing drugs that are not regarded as antiinfectives for those that kill NR Mtb. Here, we report finding such a drug in an HTS that combined four host-imposed conditions, some of which converted the drug into a form active on both R and NR Mtb. 相似文献